TRMT6对卵巢癌的预后和免疫微环境的影响
Jing Zhao1, Xiaona Wang1, Yazhuo Wang1
1Department of Gynecology, Hebei General Hospital, Shijiazhuang, China.
Frontiers in oncology
|November 17, 2025
概括
在卵巢癌中,m1A调节器TRMT6过度表达,与生存率低下和免疫逃逸相关. 这表明TRMT6可能通过阻碍抗瘤免疫力来驱动癌症的进展.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 卵巢癌仍然是癌症相关死亡的主要原因,需要新的治疗点.
- 如N6-甲基氨酸 (m1A) 等表转录组修饰,越来越多地被认为是它们在癌症中的作用.
- 在卵巢癌的背景下,m1A调节器TRMT6 (TRMT6) 尚未得到广泛研究.
研究的目的:
- 为了研究卵巢癌中m1A调节者的表达模式.
- 评估TRMT6在卵巢癌患者的预后意义.
- 分析TRMT6对卵巢癌中瘤免疫微环境 (TME) 的影响.
主要方法:
- 对TCGA卵巢癌数据库和临床样本的分析.
- 使用卡普兰-梅尔图表和考克斯回归的预测评估.
- 免疫组织化学,ssGSEA和CIBERSORT用于TME分析.
- 不同基因表达分析和ceRNA网络构建.
主要成果:
- 在卵巢癌组织中,TRMT6显著过度表达,并与较差的无进展和整体存活率相关.
- TRMT6是整体生存率差的独立预后因素,与晚期病理阶段相关.
- 高TRMT6表达与多个瘤透免疫细胞负相关,包括细胞毒性细胞,表明免疫逃避.
结论:
- 过度表达TRMT6是卵巢癌预后不佳的潜在生物标志物.
- 通过促进免疫逃生,TRMT6可能促进卵巢癌的进展.
- 向TRMT6可能是卵巢癌的潜在治疗策略.
更多相关视频
08:55Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
12.7K
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
18.8K
相关概念视频
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
